Lin joined Dolby Family Ventures in 2023 as a Senior Associate, where she supports the life sciences portfolio.
Prior to Dolby Family Ventures, she was a Venture Partner at Valkyrie Fund, where she played a key role in building the biotech portfolio. Her main responsibility was to identify visionary founders and companies working at the forefront of digital biology. She led investments in companies such as Meliora Therapeutics and Cache DNA.
Lin is trained as a scientist with over 15 years of experience in neurobiology and bioengineering. As a postdoctoral fellow at Stanford University, Lin developed a series of protein tools for non-invasive imaging, which have been employed for in vivo pharmacological screening. As a graduate student, Lin studied how neurons and microglia communicate with each other and how their interactions impact memory formation and cognitive decline.
Lin received a PhD in Neuroscience from University of Helsinki, Finland, and is an alumnus of the Stanford Graduate School of Business Ignite Program in Entrepreneurship and Innovation.